AbbVie Inc. ABBV

Key data

The business

AbbVie is an immunology drug company that outlived its own blockbuster. For a decade Humira, an anti-inflammatory injection for rheumatoid arthritis, Crohn's and psoriasis, was the best-selling drug on earth. Its US patents expired in 2023 and cheaper copies arrived. AbbVie saw the cliff coming and built two successors in the same diseases, Skyrizi and Rinvoq, and has spent three years moving patients and prescribers onto them. Today those two are the growth engine and Humira is the melting ice cube. The rest is a grab bag: Botox and aesthetics from the Allergan deal, an oncology franchise, and a neuroscience business with migraine and Parkinson's drugs. The moat is the hardest kind in pharma to copy, a stack of patents and trial data on drugs doctors already trust, but it is a moat with an expiry date stamped on every brick, which is why the whole company is organized around what replaces the last winner.

The numbers

Franchise dollars for Skyrizi, Rinvoq and Humira were not pulled this run, so the split below is qualitative and the tables are consolidated. The shape is not in doubt.

Read the quarters top to bottom and the story is the swing from Q3 2025, when net income fell to $186M on acquisition write-downs, to Q2 2026 at $3.6B. Revenue of $17.0B was up 10 percent on the same quarter a year earlier, and the company kept 75 cents of each sales dollar as gross profit against 72 the year before, the margin widening the 10-Q calls out directly. The prior watch, margins against a climbing debt load, held on the margin side: the margin expanded even as the Apogee deal and an August bond sale pushed debt higher. Adjusted EPS of $3.65 topped management's $3.61 guidance, the fourth quarter running above the guide.

Across the years the whole trauma is visible: GAAP net income collapsing from $11.8B to about $4.3B as Humira lost exclusivity, then staying there while amortization of Allergan and Humira intangibles, real charges but non-cash, sits on the reported line. Revenue troughed at $54.3B in 2023 and has climbed back to $61.2B, and the first half of 2026 ran $32.0B, up 11 percent. The recovery is real and it is Skyrizi and Rinvoq. Consensus carries revenue to $78.7B by 2028, up about 29 percent from 2025, roughly 9 percent a year, on the premise the successors take share faster than Humira sheds it. The variant this memo holds is narrow: the 72 multiple is an accounting artifact of write-downs on deals AbbVie already paid cash for, not a weaker business, and the print that settles it is Skyrizi plus Rinvoq combined revenue against the 2027 Humira erosion curve.

Cash tells the sober half. Operating cash flow slid from $24.9B in 2022 to $19.0B in 2025 while long-term debt ranged from $59B to $67B across the period, and in September AbbVie closed the $10.9B Apogee purchase at $135.11 a share, funded with a term loan and the August bonds. Net debt is now about 3.0 times EBITDA and rising.

Management

Insiders are sellers, not buyers: no purchases in twelve months against $18.9M of sales across six filings, the largest an $8.2M officer sale on August 14. The vendor feed does not carry 10b5-1 status, so plan status is not disclosed, and none of it is large enough to read as a signal. Capital allocation is the more telling record. Buybacks are modest for a company this size, about $1.0B in 2025 and $1.5B in the first quarter of 2026, because the balance sheet, not the share count, is the priority: AbbVie carries negative book equity, a legacy of the Allergan deal and years of returning more than it earned. CEO Robert A. Michael runs the same playbook as his predecessor, pay the dividend, buy successors before the cliff, lever up to do it. Apogee is that playbook again.

How it fails or surprises you

Medicare sets the price. Skyrizi and Rinvoq are exactly the high-revenue drugs the Medicare negotiation program hunts. Selection for a future round, or a hard formulary exclusion by a large payer, would cap the very franchises the $78B revenue case rests on. Watch the negotiation lists and net-price disclosures through 2027; one named cut resets the growth slope.

Apogee and the next successor (right tail). AbbVie just paid $10.9B for Apogee's longer-acting immunology antibodies, aimed at the same diseases Skyrizi and Rinvoq now own. If one reads out well in atopic dermatitis, AbbVie extends the franchise past the patent worry the market discounts today, and the deal is in no estimate yet. The first pivotal data is the tell.

The number the read explains least. GAAP profit is $4.2B on $61B of revenue, and the memo waves the 72 multiple off as amortization. If instead those charges track real erosion, Humira falling faster than the successors climb, the cheap-on-adjusted story is the trap. The print that proves it: Skyrizi plus Rinvoq growth decelerating while Humira stays in freefall.

Closing thoughts

This is the middle world, where a specific print settles it. The market already knows the Humira cliff and the successor recovery, and prices the stock near the top of its twelve-year range on faith that the two drugs compound to roughly $18 of earnings by 2028. Your edge, if you have one, is a cleaner read on whether the reported-versus-adjusted gap is accounting noise or decay, and that read converts the day combined successor revenue either clears or misses the Street's build. The fatter tail is judgment, but I lean modestly to the upside: the margin expansion and the 10 percent top line say the recovery has momentum, and the left tail, a payer or Medicare shock, is slow-moving and visible before it lands. What is at risk if it breaks is the premium multiple, not the survival of the company.

The bet is still that Skyrizi and Rinvoq grow faster than Humira fades, and that doctors and patients keep moving onto them in the high-priced US market. It breaks the quarter those two franchises decelerate while Humira stays in freefall, and the pair of numbers that tells you first is combined successor revenue against the Humira line, quarter over quarter. The memo is wrong the quarter they stop diverging in AbbVie's favor.